financetom
Business
financetom
/
Business
/
US extends comment deadline on Biden-era LNG study to protect approvals
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US extends comment deadline on Biden-era LNG study to protect approvals
Jan 22, 2025 1:38 PM

WASHINGTON (Reuters) - The U.S. has extended the comment period on a federal study of the economic and environmental impacts of the booming liquefied natural gas (LNG) export business after advisers had urged President Donald Trump to take a patient approach to prevent approvals from getting overturned in court.

The U.S. Department of Energy said late on Tuesday that it is extending the comment period from Feb. 18 to March 20 in order to get "appropriate stakeholder input."

Trump has promised swift action on reversing former President Joe Biden's pause on the LNG export approvals to big markets in Asia and Europe. On his first day in office, Trump lifted the freeze by ordering the DOE to resume considering the applications.

Actually approving exports, however, will take time. Trump's advisers had urged him to take a patient approach to restarting approvals for LNG exports, fearing rapid approvals would only get overturned in court, Reuters reported on Jan. 7.

The advisers had recommended an extension in the comment period to allow time for pro-LNG interests to challenge the study and help thwart any potential lawsuits when they approve the pending export permits.

While the U.S. became the world's largest LNG exporter in 2023, Biden's moratorium delayed projects including Venture Global's CP2 project, the Commonwealth LNG plant, and Energy Transfer's Lake Charles complex, all in Louisiana.

Biden had ordered the pause about a year ago in order to conduct the study, which his administration said showed that government should be cautious about the climate impacts of unfettered LNG exports.

The DOE also said it directed the office of fossil energy carbon management to resume consideration of pending LNG export applications.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Illinois Tool Works forecasts 2025 profit below estimates
Illinois Tool Works forecasts 2025 profit below estimates
Feb 5, 2025
Feb 5 (Reuters) - Illinois Tool Works ( ITW ) on Wednesday forecast annual profit below Wall Street expectations, as high borrowing rates and sticky inflation force customers to slow investments on industrial equipment. Shares of the company were down 3% before the bell. Higher borrowing costs have reduced corporate spending, muting the impact of steady demand from the automotive...
Equinor Unveils $5 Billion Buyback, Trims Renewables Spending As Oil & Gas Output Rises
Equinor Unveils $5 Billion Buyback, Trims Renewables Spending As Oil & Gas Output Rises
Feb 5, 2025
Equinor ASA ( EQNR ) shares are trading lower after the company reported fourth-quarter FY24 results. Revenue and other income fell 5% year-over-year (Y/Y) to $27.654 billion and adjusted revenue declined 7% Y/Y to $26.418 billion. The consensus estimate stood at $25.973 billion. Total equity liquids and gas production decreased 6% Y/Y to 2,072 mboe per day, with equity liquids production falling 6% Y/Y to 1,081 mboe per day...
EyePoint's Phase 2 Trial of Duravyu to Treat Diabetic Macular Edema Meets Endpoints; Shares Still Slump Pre-Bell
EyePoint's Phase 2 Trial of Duravyu to Treat Diabetic Macular Edema Meets Endpoints; Shares Still Slump Pre-Bell
Feb 5, 2025
09:12 AM EST, 02/05/2025 (MT Newswires) -- EyePoint Pharmaceuticals ( EYPT ) reported six-month results from a phase 2 trial of Duravyu to treat diabetic macular edema that met primary and secondary endpoints, but its shares still slumped in premarket trading. The company said the trial demonstrated clinically meaningful outcomes, such as continued safety with no Duravyu-related ocular or systemic...
Feb 5, 2025
...
Copyright 2023-2026 - www.financetom.com All Rights Reserved